American Society of Interventional Pain Physicians News | April 6, 2016
ASIPP Annual Meeting: A Meeting of Innovations in IPM for Success
As we get even closer to the Annual Meeting, I would like to re-emphasize some of the issues we are focusing on. As you know, interventional pain management is going through a tumultuous phase. Consequently, among various steps taken, we are incorporating the use of regenerative medicine for managing chronic pain into interventional pain management. The basic tenet of regenerative medicine is to:
- rejuvenate and
- restore biological function that has been lost to age, disease, injury, or congenital abnormalities by cellular tissue and organ substitutes.
These are exciting times to learn and incorporate regenerative medicine into your practice.
We will have two substantial lectures by iconic and eminent physicians regarding the current utility and future of regenerative medicine.
- THE CURRENT LANDSCAPE OF REGENERATIVE MEDICINE by Keynote Speaker, William D. Murrell, MD will cover the evolution and dynamics of regenerative medicine and also touch on incorporating it into interventional pain management.
William D. Murrell, MD
, is an internationally known regenerative medicine specialist, with some even considering him to be the father of regenerative medicine. He has held many positions in this young and dynamic specialty.
- APPLICATION OF REGENERATIVE MEDICINE IN SPINAL PAIN by Keynote Speaker Kenneth Pettine, MD,a spine surgeon who has performed both basic and clinical research as approved by the FDA to define the role of regenerative medicine in spinal pain. His motto is "Friends don't let friends get fused." Dr. Pettine has published extensively about spinal disorders, including arthroplasty, and has incorporated regenerative medicine in managing spinal pain.
Come and enjoy a once-in-a-lifetime opportunity to listen to these two great physicians on regenerative medicine with a focus on interventional pain management.
Apart from this, we also have multiple other seminars including
2 lunch symposiums (no CMEs) entitled:
1. Patient Variability and the Dynamic Nature of Pain: Customizing
Therapy with Multiple Waveform Options
Moderator: Richard Rauck, MD
, James North, MD and Louis Raso, MD
(Sponsored by Boston Scientific)
2. Wireless Neuromodulation Innovation for Pain Management
Richard North, MD and Sunil Pachal, MD
(Sponsored by Stimwave)
As you know, other important aspects includes a tribute to Dr. Prithvi Raj on Friday, April 15 and the following lectures:
- Raj-Racz Distinguished lecture series will include a presentation from me describing "Interventional Pain Management: The Time of Our Lives" and a presentation by Albert Telfeian, MD, PhD titled "Evolving Concepts of Endoscopic Disc Decompression."
- Manchikanti Distinguished Lecture by Robert Laszewski, national health care expert, titled "Strategies for the Survival of Independent Practice in the Era of Regulation and Empowered Insurance and Hospital Industry".
And many more sessions on practice management, emerging concepts and controversies, spinal cord stimulation, current utility and future of interventional techniques, and, finally, controlled substance management.
Don't miss the greatest opportunity available this year for interventional pain physicians. Register now or read the Annual Meeting brochure for more information.
ASIPP 2016 Annual Meeting
Mobile App is now available
Download the 2016 ASIPP Annual Meeting Mobile Application at the app store to access schedules, speakers, lectures, exhibitors, attendees and more!
- Search "ASIPP 18th Annual" and download the free app. You should have received an e-mail from Cloud Compass with your Registration Code
- To access by computer use the Event URL: https://crowd.cc/asipp-annual
- A second option for accessing meeting presentations is through the ASIPP File Share: https://asippfiles.sharefile.com/ - Use the E-mail address: firstname.lastname@example.org and Password: ASIPPam@2016
CMS touts ICD-10 implementation success but Interventional Pain Management Practices May Not Agree! Use of the ASIPP® new ICD-10-CM Pocket Guide Can Help Ease the Burden!
The initial impression of ICD-10 implementation was that it went well for both providers and CMS, however, shortly after the October 1, 2015 date when Medicare claims began processing, providers found out otherwise. In some cases, Interventional Pain Management providers continue to struggle with "finding the right code" to report for their patient's condition.
CMS released a publication "Clarifying Questions and Answers Related to the July 6, 2015 CMS/AMA Joint Announcement and Guidance Regarding ICD-10 Flexibilities" http://tinyurl.com/CMS-ICD-10-ClarifyQ-A that provided additional details as to how this ICD-10 family of codes "free pass" was going to work.
In short, CMS stated, "The recent Guidance does not change the coding specificity required by the NCDs and LCDs. Coverage policies that currently require a specific diagnosis under ICD-9 will continue to require a specific diagnosis under ICD-10. It is important to note that these policies will require no greater specificity in ICD-10 than was required in ICD-9, with the exception of laterality, which does not exist in ICD-9. LCDs and NCDs that contain ICD-10 codes for right side, left side or bilateral do not allow for unspecified side."
What this means is that:
- Interventional Pain Management providers are still being held responsible for reporting the correct ICD-10 code or risk Medicare claims denials.
- Many Interventional Pain Management procedures are included in the various Medicare contractor's Local Coverage Policies (LCD) and include very specific lists of ICD-10 codes that meet medical necessity for the diagnostic and therapeutic procedures.
- In some cases, Medicare contractors have separate LCD policies for each type of interventional pain procedure and often multiple pages in length.
Don't be one of the providers that have the misunderstanding if they report a valid ICD-10-CM code in the same family of codes, Medicare will accept that.
Busy Interventional Pain Management providers don't have time to check the Medicare LCD each time they perform a procedure.
Make your medical practice easier and use the ASIPP® new ICD-10-CM Pocket Guide for assistance navigating through the complexity of ICD-10 coding.
This book is 5.25 x 8.25 and can easily be placed in your jacket or any carrying case. For only $400 you will receive both the electronic and paper versions. You can recover your cost by avoiding mistakes in just one single case.
Order immediately to avoid any future losses. Get it for yourself and get copies for all your partners and staff. Multiple copies can be transferred to your EMR and save you money.
Also take a 10% discount for 5-9 copies or a 20% discount for 10 copies or more.
ASIPP to Hold Didactics on Disc Decompression, Imaging, Controlled Substance, Practice Management, Interventional Techniques in Memphis June 9-10,
Cadaver workshop June 11, 12
Here is an early look at the June schedule of meetings that ASIPP has in store for you! Meeting Brochures and Registration will be available soon!
Lumbar Endoscopic Spinal Decompression Hands-on Cadaver Workshop and Online Lectures
Basic, Intermediate and Advanced Interventional Techniques
Click HERE to register
Comprehensive Review of Interventional Techniques and Hands on Cadaver Workshop
Click HERE to register
Comprehensive Imaging Review in Interventional Pain Management and Competency Exam
Comprehensive Review Course of Controlled Substance Management and Practice Management and Competency Examination
ABIPP Part I Examination June 11
250 North Main Street
, TN, 38103
ACP Calls on Government to Curb Drug Prices
Reining in the cost of prescription drugs in the U.S. will mean going beyond setting list prices, and looking at issues of regulatory approval, patents and intellectual property, assessment of value and cost-effectiveness, and health plan drug beneﬁts, according to the American College of Physicians (ACP).
In a position paper in the Annals of Internal Medicine, ACP argued that increasing price transparency, curbing patent extensions, and enabling Medicare to negotiate volume discounts are essential strategies for keeping the rising cost of prescription drugs in check.
Majority of Opioid Overdose Patients Still Prescribed Opioids
The vast majority of patients who experience an opioid overdose continue to receive opioids to manage their pain, a new study has found. Perhaps not surprisingly, the risk for subsequent overdose in these patients is extremely high.
The study, which was published inAnnals of Internal Medicine(2016;164:1-9), revealed that among a population of 2,848 commercially insured patients tracked between 2000 and 2012, 91% were dispensed opioids even after experiencing an overdose (over a median follow-up of 299 days). Overall, 7% of these patients had a repeated opioid overdose; at two years, the cumulative incidence of repeated overdose was 17% among those receiving large doses of opioids, 15% among those receiving moderate doses, 9% among those receiving low doses and 8% among those receiving painkillers other than opioids. A large dose was defined as 100 mg or more of morphine-equivalent dosage (MED); a moderate dose was 50 to 100 mg MED; and a low dose was less than 50 mg MED.
FDA Issues Draft Guidance for Development of Abuse-Deterrent Opioids
The US Food and Drug Administration (FDA) has announced the steps it plans to take in order to expand the use of abuse-deterrent opioids.
The draft guidance, titled "General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products," aims to encourage industry efforts to promote pain medications developed to curb abuse. It advocates for generic versions of abuse-deterrent formulations, but it also stresses the importance of ensuring that these painkillers should be no less abuse-deterrent than brand-name versions.
Clinical Pain Advisor
Are US reimbursement trends stifling medical device innovation?
The increasing clout of hospital General Purchasing Organizations (GPOs), insurers and other large payors in US medical device purchasing and reimbursement may be hindering innovation, R&D and quality issues in the relentless effort to drive down healthcare costs.
Comments by small- and mid-sized US medical device firms in Emergo's 2016 industry outlook survey reflect recent US market dynamics whereby more physicians working for hospitals and other large healthcare providers has resulted in these organizations having a much larger influence on decisions as to which and what kinds of devices are purchased. (53 word sentence, break into pieces)
Using Ibuprofen After Surgery: Does It Increase Bleeding Risk?
New research suggests that ibuprofen does not increase the risk of bleeding after plastic surgery procedures.
Published in Plastic and Reconstructive Surgery, a report outlines the results of a systematic review and meta-analysis of studies comparing ibuprofen with other pain medications for patients undergoing plastic surgery-related operations.
The researchers reviewed a total of 881 publications. After examining their findings, they found 4 studies in which 443 patients were randomly assigned to ibuprofen or other medications. Procedures included in the study: cosmetic facial surgery, breast cancer surgery, hernia repair, and skin cancer surgery and reconstruction.
Clinical Pain Advisor
ER Naltrexone Associated With Lower Rate of Opioid Relapse
Extended-release naltrexone is associated with a lower rate of opioid relapse than usual treatment among criminal justice offenders, according to a study published in theNew England Journal of Medicine.
Joshua D. Lee, MD, from the New York State Psychiatric Institute in New York City, and colleagues conducted an open-label trial to compare a 24-week course of extended-release naltrexone with usual treatment for the prevention of opioid relapse among adult criminal justice offenders with a history of opioid dependence. Participants (153 assigned to extended-release naltrexone and 155 to usual treatment) were followed for the primary outcome of time to an opioid-relapse event.
Pfizer and Allergan call off their $160 billion merger after U.S. move to block inversions
The Dublin-based Botox-maker Allergan announced early Wednesday it would abandon its mega-merger with U.S. pharmaceutical giant Pfizer after new government regulations made the tax advantage of the cross-Atlantic deal more difficult to achieve.
The move is a huge victory for the Obama administration in its campaign against inversions, in which U.S.-based companies buy or merge with a smaller foreign firm and move their headquarters overseas in order to lower their tax bill. The Treasury Department released new regulations Monday to stem the tide of such inversions and Pfizer and Allergan spent two days scrambling to determine whether their merger still made financial sense.
Value-Based Insurance Program Raises Compliance
Giving patients economic incentives to participate in health screenings and take their prescribed medications resulted in decreased hospitalizations and increased medication adherence, a small study has found.
"The positive results in this case should encourage other payers to incorporate reduced cost sharing for high-value services across entire episodes of care in their benefit plans," wrote Richard Hirth, PhD, of the University of Michigan, in Ann Arbor, and colleagues in the April issue of
State Society News
Mark your calendar: GSIPP 12th Annual Pain Summit meeting set
The Georgia Society of Interventional Pain Physician have set their meeting dates for 2016.
GSIPP 12th Annual Pain Summit
April 22-24, 2016
The Ritz Carlton Lodge Reynolds Plantation
FSIPP Meeting May 20-22, 2016
The Florida Society of Interventional Pain Physicians will hold its annual meeting in 2016 on May 20-22.
The 2016 Annual Meeting, Conference and Trade Show
Interventional Pain Management:
A Diagnostic and Therapeutic Pathway to Restoration of Function
will be held at the
8701 World Center Drive, Orlando, FL 32821
FSIPP is also offering 2 concurrent programs:
To register online, please select from the choices below.
- Safe Opiate Prescribing Course - no charge, but you need to be registered for the annual meeting.
- The Business of Pain Course on Saturday, May 21 - $150.00
2016 FSIPP Members
Early Registration Rate: $449.00 through 4/1/2016
(Late Registration Rate: $525.00 after 4/1/2016)
Please send your State Society meetings and news to: Holly Long at email@example.com
To view or post a job, please go to: http://jobs.asipp.org/home
To receive a member discount for posting a job, use member code: 20Member